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Expected outcome and costs
† Discussion
background: Overweight and obesity are an epidemic in Western society, and have a strong impact on fertility. We studied the con-
sequences of overweight and obesity with respect to fecundity, costs of fertility treatment and pregnancy outcome in subfertile women.
methods: We searched the literature for systematic reviews and large studies reporting on the effect of weight on both fecundity and
pregnancy outcome in subfertile women. We collected data on costs of treatment with ovulation induction, intrauterine insemination and
in vitro fertilization, as well as costs of pregnancy complications. We calculated, for ovulatory and anovulatory women separately, the number
of expected pregnancies, complications and costs in a hypothetical cohort of 1000 normal weight, overweight and obese women each.
results: In our hypothetical cohort of 1000 women, compared with women with normal weight, live birth was decreased by 14 and 15%
(from 806 live births to 692 and 687 live births) in overweight and obese anovulatory women, respectively, for ovulatory women it was
decreased by 22 and 24% (from 698 live births to 546 and 531 live births), respectively. These outcomes were associated with an increase
in the number of complications and associated costs leading to cost per live birth in anovulatory overweight and obese women were 54 and
100% higher than their normal weight counterparts, for ovulatory women they were 44 and 70% higher, respectively.
conclusions: Overweight and obese subfertile women have a reduced probability of successful fertility treatment and their pregnan-
cies are associated with more complications and higher costs.
Key words: infertility / body mass / assisted reproduction / cost / effectiveness
Introduction
The prevalence of overweight and obesity varies in populations and is
estimated to range from 5% in some developing countries to .30% in
developed countries (James et al., 2004). The World Health Organiz-
ation deﬁnes overweight as a body mass index (BMI)  25 kg/m2, and
obesity as a BMI  30 kg/m2 (World Health Organisation, 2000).
Considering the trends in childhood obesity, a signiﬁcant increase in
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obesity related subfertility can be anticipated in the future (Schokker
et al., 2007). Nowadays, the rate of obesity in women of child
bearing age is 12% in Western Europe and 25% in North America
(Butler, 2004; Linne´, 2004; Haslam and James 2005; Watson, 2005).
The strongest obesity related effect on fertility is anovulation. Poly-
cystic ovarian syndrome (PCOS), the most noted cause of anovula-
tion, is furthermore exacerbated by increased insulin resistance and
hyperinsulinemia associated with overweight and obesity (Pasquali
et al., 2007). In 65% of patients with PCOS, obesity therefore contrib-
utes to anovulation (Pasquali et al., 2003). On the other hand, even
obese women with an ovulatory cycle have a lower chance of spon-
taneous conception (Jensen et al., 1999; Van der Steeg et al., 2007).
In cases of chronic anovulation, ovulation induction (OI) with
clomiphene citrate in overweight and obese women results in lower
ovulation rates (Imani et al., 1998) and lower cumulative live birth
rates for women with a BMI. 30 kg/m2 (Legro et al., 2007).
McClure et al. (1992) showed that in overweight women ovulation
rates are lower due to higher cancellation rates, but if OI is successful
no difference is found in pregnancy rates in different weight categories.
Mulders et al. (2003) also found obesity to be associated with higher
cancellation rates and substantially higher miscarriage rates leading to a
lower live birth rate per started cycle. This decreased success rate is
however not found in all studies (Balen et al., 2006).
The literature on the impact of body weight on the effectiveness of
intrauterine insemination (IUI) is just as for OI, inconsistent. Koloszar
et al. showed a negative impact of increasing body weight on the
success rates of IUI, butWang et al. (2004) could not conﬁrm this ﬁnding.
Furthermore, several retrospective studies have shown a negative
impact of overweight and obesity in women on the outcome of
in vitro fertilization (IVF) (Lashen et al., 1999; Wang et al., 2000;
Koloszar et al., 2002; Fedorcsak et al., 2004). The ongoing pregnancy
rate and live birth rate is however consistently decreased especially
due to an increased miscarriage rate in women with obesity
(Wang et al., 2002; Lintsen et al., 2005; Maheshwari et al., 2007).
Apart from these obesity related fertility problems, there is indisputa-
ble evidence that pregnancy in overweight and obese women is associ-
ated with an increased risk of complications, leading to higher maternal
and neonatal morbidity and mortality and increased costs (Cedergren,
2004; Linne´, 2004; Sebire et al., 2001). Pregnancy complications associ-
ated with obesity are hypertensive disorders, gestational diabetes, pro-
longed duration of labour, increased need of operative delivery,
macrosomia, shoulder dystocia and increased blood loss (Garbaciak
et al., 1985; Edwards et al., 1996;Weiss et al., 2004). Obesity is further-
more associated with an increased risk of adverse pregnancy outcomes
such as unexplained stillbirth (Cnattingius et al., 1998; Linne´, 2004;
Kristensen et al., 2005) and neonatal admissions (Usha Kiran et al., 2005).
In view of the issues stated above, it is likely that overweight and
obesity have a negative impact on the outcome as well as the costs of
fertility treatment. The aim of this article is to conceptualize the
impact of overweight and obesity on fertility treatment and the resultant
pregnancies, in terms of effectiveness, costs and cost-effectiveness.
Methods
We developed a framework within which the consequences of fertility
treatment and outcomes of resultant pregnancy can be evaluated simul-
taneously for subfertile women in different body weight categories. We
performed systematic reviews to obtain information on outcomes and
costs to generate cost-effectiveness estimates for inclusion in decision ana-
lytic models. To do so, we searched the literature for evidence on the
effect of obesity on spontaneous pregnancy chances, success of assisted
reproduction technologies (ART), as well as pregnancy outcome.
Weused the following electronic databases: PubMed, Embase, DARE and
the Cochrane Library to initially search for systematic reviews on each of the
subjects. In absence of reviews, we identiﬁed large, reliable studies.
To identify studies that reported on the association between obesity and
spontaneous pregnancy chances we combined the key words (‘obesity’,
‘overweight’ or ‘BMI’) and (‘pregnancy’ or ‘fertility’). By adding the key
words (‘ART’, ‘IUI’) and (‘OI’) we looked for studies reporting on the
effect of obesity on these treatments. To identify studies reporting on the
association between obesity and pregnancy outcome, we used the key
words: (‘obesity’, ‘overweight’ or ‘BMI’) and (‘pregnancy outcome’).
We included studies reporting on maternal morbidity as well as preg-
nancy outcome. The reported odds ratios (ORs) in the reviews were
used, or if not available, calculated by using a 2  2 table cross classifying
BMI and one of the aforementioned outcomes. These ORs were used as
input for calculating the additional impact of overweight and obesity on
both fecundity as well as pregnancy.
The economic analysis was performed from a hospital perspective.
Costs of fertility treatments were obtained from a series of Dutch
studies, which reported on the costs of OI, IUI and costs of IVF
(Goverde et al., 2000; Eijkemans et al., 2005). Furthermore, we looked
for studies reporting on costs of pregnancy in overweight women and
costs of pregnancy complications in these women. To do so, we per-
formed a search of several major journals in obstetrics and gynaecology
for economic evaluations. We looked for studies that reported on the
costs of each of the complications miscarriage, pre-eclampsia, gestational
diabetes and Caesarean delivery. We assumed no difference in multiple
pregnancy rates between different weight categories (Esinler et al., 2008).
Next, we assessed the impact of overweight and obesity on the costs
and effects of fertility treatments. To achieve this, we distinguished
between the case of ovulatory women and the case of anovulatory
women. For each of these situations, we considered women with
normal weight, overweight and obese women. According to the WHO
normal weight is deﬁned as a BMI between 20 and 25 kg/m2, overweight
as a BMI between 25 and 30 kg/m2 and obesity as a BMI over 30 kg/m2.
Because of differences in deﬁnitions of overweight and obesity in some
studies we used in our review, we could not use the very strict BMI cut
off points proposed by the WHO for our different weight groups.
We then constructed a theoretical model, simulating the situation
where women were treated for their subfertility. For each of the six cat-
egories, i.e. anovulatory women with normal weight, anovulatory over-
weight women and anovulatory obese women and ovulatory women
with normal weight, ovulatory overweight women and ovulatory obese
women, we calculated the expected pregnancy rates, the expected
number of fertility treatments and the expected number of pregnancy
complications for a hypothetical group of 1000 women. We performed
multiple sensitivity analyses on the following variables success rate of IVF
(range 40–60%), success rate of OI (range 70–90%) and IUI (range
30–50%). With these ﬁgures we calculated and then plotted in two
ﬁgures different success rates of ART against the costs per live birth in ano-
vulatory and ovulatory women in different weight categories.
Results
Literature identiﬁed
The search for studies on the association between spontaneous preg-
nancy chances in overweight women revealed two reviews by Jensen
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et al. (1999) and Gesink Law et al. (2007) as well as the study of Van
der Steeg et al. (2007). The results of these studies are shown in
Table I. Both reviews as well as the study of Van der Steeg et al.
showed that overweight women take longer to conceive than
normal weight women. The reviews were retrospective studies in a
cohort of women not seeking medical help for any subfertility,
whereas Van der Steeg et al. studied women in fertility clinics. On
the basis of these results, we assumed that among obese ovulatory
women spontaneous pregnancy chances were 90% of those in
normal weight or overweight women. Moreover, we assumed that
spontaneous pregnancy chances prior to and in between ART
cycles was 10% in all groups.
From the literature no unequivocal conclusion could be drawn
about the inﬂuence of obesity on IUI. Whereas Wang et al. (2004)
reported an increased probability of success of IUI in women with a
BMI. 30 kg/m2, Koloszar et al. reported exactly the opposite, i.e.
a decrease of success of IUI with increasing BMI. In view of these con-
ﬂicting results on IUI, for purpose of this review we considered no
effect of BMI on IUI.
Maheshwari et al. (2007) published a systematic review of the litera-
ture from 1960 until 2006 on the outcome of IVF for overweight and
obese women. They reported an OR for pregnancy after IVF of 0.71
(CI 95% 0.62–0.81) for women with a BMI . 25 kg/m2 compared
with women with a BMI between 20 and 25 kg/m2, and for women
with a BMI . 30 kg/m2 even 0.68 (CI 95% 0.55–0.83) (Table I).
We applied these ORs in our model. Maheshwari et al. (2007) also
found that overweight women require more total units of gonado-
trophins during hyperstimulation for IVF, but these additional costs
were not considered in the present analysis.
We found one meta-analysis and three studies that reported on
the impact of BMI on the effectiveness of OI in anovulatory
women (Table II) (Imani et al., 2002; Al-Azemi et al., 2004;
Mulders et al., 2003; Balen et al., 2006). The study of Al-Azemi
et al. showed a negative impact of obesity on live birth rate after
OI with clomiphene citrate. The meta-analysis of Mulders et al. did
not show a signiﬁcant impact of BMI on the fecundity after OI with
gonadotrophins. However, they found higher cancellation rates per
cycle (OR 1.9) and higher miscarriage rates in the obese group
(OR 3.1), thus leading to lower ongoing pregnancy rates per
started cycle.
Balen et al. studied anovulatory women with a BMI up to 35 kg/m2
and also did not ﬁnd a signiﬁcant difference in pregnancy rates after OI
with gonadotrophins in overweight and obese women compared with
women of normal weight (Balen et al., 2006). Imani et al. found among
anovulatory women a hazard ratio of 0.92 for obese versus lean
women for ovulation after OI with clomiphene citrate, but they also
did not ﬁnd a difference in live birth chances between the weight
groups (Imani et al., 2002). We therefore assumed in our analysis
that there is no inﬂuence of BMI on pregnancy rates after OI in ano-
vulatory women.
Table III shows the additional risk of obstetric complications due to
overweight and obesity. We applied meta-analyses conducted by Chu
et al. (2007a, b, c) and Cnossen et al. (2007). These studies report
that there is an additional risk of stillbirth, Caesarean delivery, pre-
eclampsia and gestational diabetes with increasing BMI. Fedorcsak
et al. (2004) studied the impact of overweight in women undergoing
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Table II Odds ratio’s of pregnancy chances of overweight and obese anovulatory women following OI
Author Study period Study population Study design Outcome measure Results
Azemi Not reported Infertile women undergoing CC–OI Retrospective cohort study Live birth OR 0.74* (0.39–1.4) for BMI 25–29
OR 0.15* (0.07–0.30) for BMI .30
Mulders 1986–2002 Infertile women undergoing gonadotrophin-OI Meta analysis Pregnancy OR 1.22 (CI 95% 0.77–1.93) obese versus lean women
Cancellation rate OR 1.86 (CI 95% 1.13–3.06)
Miscarriage rate OR 3.05 (CI 95% 1.45–6.44)
Balen 2002–2003 After three cycles CC failed OI –. gonadotrophins Prospective cohort study Pregnancy OR 1.3* (0.71–2.2) for BMI .25
OR 0.99* (0.48–2.0) for BMI. 30
Imani 1993–1995 Infertile women undergoing CC–OI Prospective cohort study Ovulation OR 0.92 (0.88–0.96) obese versus normal weight
live birth OR 1.00 (0.97 to 1.04)
CC, clomiphene citrate; OI, ovulation induction; BMI, body mass index; *, calculated OR.
..........................................................................................................................................................................................................................................................
Table III Odds ratios of maternal and fetal complications in overweight and obese women
Author Study period Study population Study design Outcome measure Results
Fedorcsak 1996–2002 IVF/ICSI Retrospective cohort Abortion, 6wks OR 2.0* (CI 95% 1.1–3.7) for BMI. 25
Chu (b) 1980–2005 Birth registries, clinical medical records etc. Meta analysis Stillbirth OR 1.5 (CI 95% 1.1–1.9) for overweight women
OR 2.1 (CI 95% 1.6–2.7) for obese women
Cnossen 1980–2006 Cohort (prospective and retrospective) Meta analysis Pre-eclampsia LRs (95% CI) 1.7 (0.3–11.9) for BMI  25 and 0.73
(0.22–2.45) for BMI, 25 (OR 2.3)
LRs 2.7 (1.0–7.3) for BMI  35 and 0.86 (0.68 to –1.07)
for BMI, 35 (OR 3.7)
Chu (c) 1980–2005 Cohort (prospective and retrospective) Meta analysis Cesarean delivery OR 1.5 (CI 95% 1.3–1.6) for overweight women
OR 2.1 (CI 95% 1.9–2.3) for obese women
OR 2.9 (CI 95% 2.3–3.8) for severely obese women
Chu (a) 1980–2006 Cohort (prospective and retrospective) Meta analysis Gestational diabetes OR 2.1 (95%CI 1.8–4.2) for overweight women
OR 3.6 (CI 95% 3.1–4.2) for obese women
OR 8.6 (CI 95% 5.1–16) for severely obese
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Table IV presents expected costs of fertility treatment and preg-
nancy complications. We used several studies on costs of pregnancy
complications and calculated the costs presented in euro’s using the
current exchange rates (Chen et al., 2001; Graziosi et al., 2005;
Barton et al., 2006; Moss et al., 2007). Furthermore, we used
studies on costs in the Netherlands for OI, IUI and IVF treatment
(Goverde et al., 2000; Eijkemans et al., 2005).
Expected outcome and costs
Table V shows the result when the model was applied on a hypothe-
tical cohort of 1000 anovulatory women. Our model represents costs
until birth, including the costs of delivery. In 1000 normal weight ano-
vulatory women, treatment with three cycles of OI and, if needed, fol-
lowed by one or two cycles of IVF, would result in 900 pregnancies.
Figure 1A shows that costs per live birth are higher for overweight
and obese anovulatory women with different success rates of OI
and IVF and these differences in costs are roughly constant over a
large range of success rates.
Of these pregnancies 90 are expected to end in miscarriage and 810
women will have an ongoing pregnancy. The expected number of
pregnancies complicated by pre-eclampsia, gestational diabetes and
Caesarean delivery, will be 81, 41 and 81, respectively, whereas
four women will suffer stillbirth. Overall, 806 women are expected
to deliver a child, for a total cost of E2430 per woman, resulting in
a cost of E3016 per live birth.
From Table V, it can also be seen that in overweight anovulatory
women the effectiveness of treatment decreases, resulting in a
........................................................................................
Table IV Costs of pregnancy complications and ART
per pregnancy
Study Complication/treatment Costs per
pregnancy
(E)
Chen et al. (2001) Cesarean delivery 3350*
Barton et al. (2006) Hypertensive disorder 8250*
Moss et al. (2007) Gestational diabetes mellitus 345*
Graziosi et al. (2005) Miscarriage 683
Goverde et al. (2000) IVF 1700*
Eijkemans et al. (2005) OI 250
Goverde et al. (2000) IUI 450*
*Calculated from US and AUS dollars and Dutch guilders.
.............................................................................................................................................................................................
Table V Hypothetical cohort of 1000 anovulatory women in different weight categories
Normal weight Overweight1 Obese2
Cohort 1000 1000 1000
Impact of overweight on OI (OR) 1 1 1
Pregnant after three cycles OI (baseline rate 80%) 800 800 800
Number of women undergoing IVF 200 200 200
Impact of weight on effectiveness IVF (OR) 1 0.71 0.68
Pregnant after two cycles IVF (baseline rate 50%) 100 71 68
Expected number of pregnancies 900 871 868
Impact of weight on miscarriage (OR) 1 2 2
Expected number of miscarriages (baseline rate 10%) 90 174 174
Number of women without ongoing pregnancy 190 303 306
Number of women with ongoing pregnancy 810 697 694
Impact of weight on pre-eclampsia (OR) 1 2.3 3.7
10% pregnancies complicated by pre-eclampsia 81 160 257
Impact of weight on gestational diabetes (OR) 1 2.1 3.6
5% pregnancies complicated by gestational diabetes 41 73 125
Impact of weight on Caesarean deliveries (OR) 1 1.5 2.1
10% pregnancies Caesarean delivery 81 105 146
Impact of weight on stillbirth (OR) 1 1.5 2.1
0.5% pregnancies stillbirth 4 5 7
Total women with live birth 806 692 687
Total costs complications (E) 1000 1788 2724
Total expected cost (*E1000) 2430 3218 4154
Cost per live birth (E) 3016 4653 6045
Cost per pregnancy (E) 3001 4618 5982
1Applied BMI (kg/m2) threshold differed from study to study (range 25–27).
2Applied BMI (kg/m2) threshold differed from study to study (range 29–35).
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decrease of the number of pregnancies and live births, an increase in
costs and a relative increase of the number of complications. This
results in a decrease in the number of live births of 114 (14%), and
an expected increase in costs of almost E800 (32%) per patient.
For obese anovulatory women, these ﬁgures are slightly worse, as
the number of live births decrease to 119 (15%), and the expected
increase in cost of approximately E1700 (71%) per patient as com-
pared with normal weight women.
Table VI shows the results for a theoretical cohort of 1000 ovula-
tory women. In 1000 normal weight ovulatory women, treatment con-
sisted of three cycles of IUI and if this was unsuccessful one or two
cycles of IVF, added with 10% spontaneous pregnancies that occur
on waiting lists or in between cycles, would result in 780 pregnancies.
Figure 1B show that over a large range of different success rates of IUI
and IVF the costs per live birth are higher for overweight and obese
ovulatory women.
Of these pregnancies 78 are expected to suffer a miscarriage and
702 women will have an ongoing pregnancy. The expected number
of pregnancies complicated by pre-eclampsia, gestational diabetes
and Caesarean delivery, will be 70, 35 and 70, respectively, whereas
four women will suffer stillbirth. Overall, 698 women are expected
to deliver a child, for a total cost of E4258 per woman, resulting in
a cost per live birth E6096.
Similarly as for anovulatory women, it can be shown that in over-
weight ovulatory women the effectiveness of treatment decreases,
resulting in a decrease of the number of pregnancies and live births,
an increase in costs and a relative increase of the number of compli-
cations. This results in a decrease in the number of live births of
153 (22%), with the expected increase in costs of E543 (13%), result-
ing in a cost per live birth of E8800. For obese ovulatory women,
these ﬁgures are worse with a decrease in live births of 167 (24%),
with the expected increase in costs of almost E1250 (29%), resulting
in a cost per live birth of E10 355.
Discussion
Overweight and obesity are an increasing problem in Western society.
In this review, we collected data on the impact of overweight and
obesity on fertility care. We found that both in ovulatory and in ano-
vulatory subfertile women overweight and obesity resulted in a
decreased fecundity and in an increase in the number of pregnancy
complications and associated costs. However, there is no proven
cause and effect between overweight and subfertility. It remains poss-
ible that excessive weight and subfertility are both symptoms of an
unknown pathology.
Our results roughly suggest that overweight leads to an additional
cost of E1500 per pregnancy and 100 fewer pregnancies per 1000
anovulatory women undergoing fertility treatment, where this is
E2500 and 150 pregnancies, respectively, for anovulatory women.
The validity of our ﬁndings depends on the robustness of our meth-
odology. We put forward a framework that can be used to encourage
development of more advanced models for generating cost-
effectiveness information through robust economic evaluation. In
our review of the literature, we found different and occasionally con-
ﬂicting results on the impact of overweight and obesity on the effect of
fertility treatment. When this was the case, we chose to consider no
effect of overweight. Furthermore the success rate of IVF decreases
with increasing BMI (Maheshwari et al., 2007), thus overweight and
obese women will have to undergo more cycles compared with
normal weight women.
As a consequence, our ﬁndings may be an underestimation of the
impact of overweight and obesity. Since the purpose of this review
was not to give exact ﬁgures on costs but to show a trend in costs
and cost-effectiveness, we feel this possible inaccuracy does not
undermine the overall conclusion.
From our analysis several issues rise. First, as a higher BMI is associ-
ated with more pregnancy complications, there is the question as to
whether women should lose weight before fertility treatment is
started. A recent retrospective analysis by Maheshwari et al. (2009)
concludes that cost of IVF is not different for several weight categories
but because of obstetric complications associated with higher BMI
women with overweight should be advised to lose weight prior to
IVF. Our analysis concurs with this conclusion and gives indicative
results that merit consideration in counselling patients and guiding
evidence-based discussions on current practice and policy.
Weight loss may be achieved by lifestyle modiﬁcation interventions,
incorporating multiple approaches (diet, exercise, behaviour). Inter-
ventions of this kind are advised as a key component for the
Figure 1 (A) Sensitivity analyses showing the effect of variation of
success rates of OI and IVF on costs per live birth in anovulatory
women. (B) Sensitivity analyses showing the effect of variations of
success rates of IUI and IVF on costs per live birth in ovulatory
women.
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improvement of reproductive function in overweight women,
speciﬁcally with PCOS (Kiddy et al., 1992; Clark et al., 1995, 1998;
Huber-Buchholz, 1999; Hoeger et al., 2004; Norman et al., 2004;
Balen et al., 2006; Tang et al., 2006), although the evidence of its
effectiveness as demonstrated in clinical studies is limited. The cost-
effectiveness of losing weight has never been assessed in large
groups of subfertile women with respect to increasing treatment
success for weight-related subfertility, prevention of complications
during pregnancy and improvement of perinatal outcome. Until this
has been demonstrated we do not think it should be obligatory for
overweight subfertile women to undergo a lifestyle intervention pro-
gramme before starting fertility treatment but in counselling patients
there should be attention for possible pregnancy complications with
increasing BMI. It is clear that losing weight takes great effort and
we feel that overweight should be considered a disease rather than
an amenable condition.
Second, apart from the unproven effectiveness of lifestyle interven-
tions in overweight subfertile women, there is the question as to
whether there should be upper limits for BMI above which couples
should not be treated. Some authors have suggested limits for BMI
for women undergoing fertility treatment, both with the arguments
of patient safety concerns, as well as a lack of effectiveness of treat-
ment of obese women (Gillett et al., 2006; Zachariah et al., 2006;
Maheshwari et al., 2007). However, we feel that from the perspective
of effectiveness of treatment, our data show that there is no reason to
withhold treatment. Although effectiveness rates decrease with
increasing BMI, the same appears true for women undergoing assisted
reproduction over the age of 40, which is a well accepted practice in
many countries. Age is however a predictable and amenable factor
considering the fact that many couples delay conception to for
example pursue career opportunities. In our opinion, studies on
weight loss interventions should show a clear increase of effectiveness
of fertility treatment and a clear decrease in pregnancy related compli-
cations, before BMI thresholds can be implemented. In conclusion, in
ovulatory and anovulatory subfertile women overweight and obesity is
associated with a decrease in the number of pregnancies, a sharp
increase in the number of complications with an additional rise of
associated costs per pregnancy. There is not enough evidence
.............................................................................................................................................................................................
Table VI Hypothetical cohort of 1000 ovulatory women in different weight categories
Normal weight Overweight1 Obese2
Cohort 1000 1000 1000
Impact of overweight on spontaneous pregnancies (OR) 1 1 0.9
Spontaneous pregnancies (baseline rate 10%) 100 100 90
Number of women undergoing IUI 900 900 910
Treatment effect of IUI (OR) 0.4 0.4 0.4
Pregnant after three cycles IUI (baseline rate 40%) 360 360 364
Number of women undergoing IVF 640 640 636
Impact of overweight on effectiveness IVF 1 0.71 0.68
Pregnant after two cycles IVF (baseline rate 50%) 320 227 216
Expected number of pregnancies 780 687 670
Impact of weight on miscarriage (OR) 1 2 2
Expected number of miscarriages (baseline rate 10%) 78 137 134
Number of women without ongoing pregnancy 298 450 464
Number of women with ongoing pregnancy 702 550 536
Impact of weight on pre-eclampsia (OR) 1 2.3 3.7
10% pregnancies complicated by pre-eclampsia 70 126 198
Impact of weight on gestational diabetes (OR) 1 2.1 3.6
5% pregnancies complicated by gestational diabetes 35 58 97
Impact of weight on Caesarean deliveries (OR) 1 1.5 2.1
10% pregnancies Caesarean delivery 70 82 113
Impact of weight on stillbirth (OR) 1 1.5 2.1
0.5% pregnancies stillbirth 4 4 6
Total women with live birth 698 546 531
Total costs complications (E) 867 1410 2103
Total expected cost (* E1000) 4258 4801 5494
Cost per live birth (E) 6096 8800 10 355
Cost per pregnancy (E) 6066 8734 10 246
1Applied BMI (kg/m2) threshold differed from study to study (range 25–27).
2Applied BMI (kg/m2) threshold differed from study to study (range 29–35).
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however to prove that losing weight will improve the outcome of fer-
tility treatment and decrease complications in pregnancies, and there-
fore strict BMI thresholds cannot be recommended yet. However,
overweight and obese subfertile women should be counselled that
overweight is a risk factor in pregnancy and is associated with
several complications in both mothers and their children.
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